Vineet Laboratories (BOM:543298) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vineet Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vineet Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Vineet Laboratories's long-term debt to total assets ratio declined from Dec. 2022 (0.06) to Dec. 2023 (0.00). It may suggest that Vineet Laboratories is progressively becoming less dependent on debt to grow their business.

Vineet Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Vineet Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vineet Laboratories LT-Debt-to-Total-Asset Chart

Vineet Laboratories Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.01

0.04

Vineet Laboratories Quarterly Data
	Mar17	Mar18	Mar19	Mar20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial											0.06	0.04	0.05	0.04	-

Vineet Laboratories LT-Debt-to-Total-Asset Calculation

Vineet Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	48.479	/	1158.492
	=	0.04

Vineet Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	0
	=

Vineet Laboratories (BOM:543298) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vineet Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Vineet Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vineet Laboratories (BOM:543298) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Vineet Laboratories Ltd (BOM:543298) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

VINEETLAB:India

Address

5-5-160, Malleswari Nilayam, Opposite Vishnu Theatre, Chintalakunta, L.B.Nagar, Hyderabad, TG, IND, 500 074

Website

https://www.vineetlabs.co.in

Vineet Laboratories Ltd Formerly known as Ortin Laboratories Limited, Unit-II is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Isopropyl-beta-D-thiogalactopyranoside and Nitrophenyl phosphate disodium salt among others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, manufacture of Drug Intermediates & Bulk Dugs.

Vineet Laboratories (BOM:543298) Headlines

No Headlines